Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles
Small interfering RNA (siRNA) for silencing genes and treating disease has been a dream since ranking as a top Breakthrough of the Year in 2002 by Science. With the recent FDA approval of four siRNA-based drugs, the potential of RNA therapeutics to become the third milestone in pharmaceutical drug d...
Main Authors: | Daniel W. Binzel, Songchuan Guo, Hongran Yin, Tae Jin Lee, Shujun Liu, Dan Shu, Peixuan Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S216225312100189X |
Similar Items
-
Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery
by: Wanyi Tai
Published: (2019-06-01) -
Expression of RNA Nanoparticles Based on Bacteriophage Phi29 pRNA in Escherichia coli and Bacillus subtilis
by: Zhang, Le
Published: (2013) -
TDP-43 prevents retrotransposon activation in the Drosophila motor system through regulation of Dicer-2 activity
by: Giulia Romano, et al.
Published: (2020-07-01) -
Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3′ Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs
by: Jiehua Zhou, et al.
Published: (2012-01-01) -
Roles of Argonautes and Dicers on Sclerotinia sclerotiorum Antiviral RNA Silencing
by: Achal Neupane, et al.
Published: (2019-07-01)